A Study of Orforglipron for the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-MAINTAIN)

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
Eli Lilly and Company
Study ID
NCT06584916
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Orforglipron — DRUG
    Administered orally
  • Placebo — DRUG
    Administered orally

Study Details

The main purpose of this study is to evaluate the efficacy and safety of orforglipron on maintenance of body weight reduction in participants who previously completed treatment with injectable tirzepatide (Zepbound) or injectable semaglutide (Wegovy) in the SURMOUNT-5 trial (NCT05822830).

Key Dates

Start date
Sep 13, 2024
Status verified
Jun 2026
Primary completion
Nov 21, 2025
Completion
Nov 21, 2025

Study Design

Enrollment
376 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Orforglipron
    Participants will receive orforglipron orally
  • Placebo Comparator: Placebo
    Participants will receive placebo orally

Primary Outcome Measure

Percent Maintenance of Body Weight Reduction Achieved in SURMOUNT-5 [ Time Frame: Week 52 ]

Locations (27)

FacilityCityStateZIPSite coordinators
Cahaba ResearchBirminghamAlabama35242-
Cahaba Research - PelhamPelhamAlabama35124-
Southern California Dermatology, Inc.Santa AnaCalifornia92701-
Encompass Clinical ResearchSpring ValleyCalifornia91978-
University Clinical Investigators, Inc.TustinCalifornia92780-
New Horizon Research CenterMiamiFlorida33165-
Rophe Adult and Pediatric Medicine/SKYCRNGUnion CityGeorgia30291-
Rocky Mountain Clinical ResearchIdaho FallsIdaho83404-
Iowa Diabetes and Endocrinology Research CenterWest Des MoinesIowa50265-
L-MARC Research CenterLouisvilleKentucky40213-
Arcturus Healthcare , PLC, Troy Internal Medicine Research DivisionTroyMichigan48098-
Prime Health and Wellness/SKYCRNGFayetteMississippi39069-
StudyMetrix ResearchCity of Saint PetersMissouri63303-
Palm Research Center SunsetLas VegasNevada89148-
Palm Research Center TenayaLas VegasNevada89128-
Weill Cornell Medical CollegeNew YorkNew York10021-
PharmQuest Life Sciences, LLCGreensboroNorth Carolina27408-
Lillestol ResearchFargoNorth Dakota58104-
Alliance for Multispecialty Research, LLCNormanOklahoma73069-
Tribe Clinical Research, LLCGreenvilleSouth Carolina29607-
WR-Clinsearch, LLCChattanoogaTennessee37421-
The University of Texas Health Science Center at HoustonBellaireTexas77401-
North Texas Endocrine CenterDallasTexas75231-
Velocity Clinical Research, DallasDallasTexas75230-
Biopharma Informatic, LLCHoustonTexas77043-
PlanIt Research, PLLCHoustonTexas77079-
Southern Endocrinology AssociatesMesquiteTexas75149-

Related coverage on Hipa.ai

Find similar trials in Birmingham, AL

By condition
Obesity / overweight
By specialty
EndocrinologyMetabolic healthWeight loss
By research site
Cahaba Research· Birmingham, ALCahaba Research - Pelham· Pelham, ALSouthern California Dermatology, Inc.· Santa Ana, CAEncompass Clinical Research· Spring Valley, CAUniversity Clinical Investigators, Inc.· Tustin, CANew Horizon Research Center· Miami, FL

Related Studies